An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma
To date, pancreatic adenocarcinoma (ADKP) is a devastating disease for which the incidence rate is close to the mortality rate. The survival rate has evolved only 2−5% in 45 years, highlighting the failure of current therapies. Otherwise, the use of photodynamic therapy (PDT), based on the...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/1/192 |
id |
doaj-22ff5a3083d6439cbf8a77ca51fc1440 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexandre Quilbe Olivier Moralès Martha Baydoun Abhishek Kumar Rami Mustapha Takashi Murakami Bertrand Leroux Clémentine de Schutter Elise Thecua Laurine Ziane Ludovic Colombeau Céline Frochot Serge Mordon Nadira Delhem |
spellingShingle |
Alexandre Quilbe Olivier Moralès Martha Baydoun Abhishek Kumar Rami Mustapha Takashi Murakami Bertrand Leroux Clémentine de Schutter Elise Thecua Laurine Ziane Ludovic Colombeau Céline Frochot Serge Mordon Nadira Delhem An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma Journal of Clinical Medicine photodynamic therapy folate-coupled photosensitizer pancreatic cancer immuno-adjuvant |
author_facet |
Alexandre Quilbe Olivier Moralès Martha Baydoun Abhishek Kumar Rami Mustapha Takashi Murakami Bertrand Leroux Clémentine de Schutter Elise Thecua Laurine Ziane Ludovic Colombeau Céline Frochot Serge Mordon Nadira Delhem |
author_sort |
Alexandre Quilbe |
title |
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma |
title_short |
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma |
title_full |
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma |
title_fullStr |
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma |
title_full_unstemmed |
An Efficient Photodynamic Therapy Treatment for Human Pancreatic Adenocarcinoma |
title_sort |
efficient photodynamic therapy treatment for human pancreatic adenocarcinoma |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-01-01 |
description |
To date, pancreatic adenocarcinoma (ADKP) is a devastating disease for which the incidence rate is close to the mortality rate. The survival rate has evolved only 2−5% in 45 years, highlighting the failure of current therapies. Otherwise, the use of photodynamic therapy (PDT), based on the use of an adapted photosensitizer (PS) has already proved its worth and has prompted a growing interest in the field of oncology. We have developed a new photosensitizer (PS-FOL/PS2), protected by a recently published patent (WO2019 016397-A1, 24 January 2019). This photosensitizer is associated with an addressing molecule (folic acid) targeting the folate receptor 1 (FOLR1) with a high affinity. Folate binds to FOLR1, in a specific way, expressed in 100% of ADKP or over-expressed in 30% of cases. The first objective of this study is to evaluate the effectiveness of this PS2-PDT in four ADKP cell lines: Capan-1, Capan-2, MiapaCa-2, and Panc-1. For this purpose, we first evaluated the gene and protein expression of FOLR1 on four ADKP cell lines. Subsequently, we evaluated PS2’s efficacy in our cell lines and we assessed the impact of PDT on the secretome of cancer cells and its impact on the immune system. Finally, we evaluate the PDT efficacy on a humanized SCID mouse model of pancreatic cancer. In a very interesting way, we observed a significant increase in the proliferation of activated-human PBMC when cultured with conditioned media of ADKP cancer cells subjected to PDT. Furthermore, to evaluate in vivo the impact of this new PS, we analyzed the tumor growth in a humanized SCID mice model of pancreatic cancer. Four conditions were tested: Untreated, mice (nontreated), mice with PS (PS2), mice subjected to illumination (Light only), and mice subjected to illumination in the presence of PS (PDT). We noticed that the mice subjected to PDT presented a strong decrease in the growth of the tumor over time after illumination. Our investigations have not only suggested that PS2-PDT is an effective therapy in the treatment of PDAC but also that it activates the immune system and could be considered as a real adjuvant for anti-cancer vaccination. Thus, this new study provides new treatment options for patients in a therapeutic impasse and will provide a new arsenal in the fight against PDAC. |
topic |
photodynamic therapy folate-coupled photosensitizer pancreatic cancer immuno-adjuvant |
url |
https://www.mdpi.com/2077-0383/9/1/192 |
work_keys_str_mv |
AT alexandrequilbe anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT oliviermorales anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT marthabaydoun anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT abhishekkumar anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT ramimustapha anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT takashimurakami anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT bertrandleroux anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT clementinedeschutter anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT elisethecua anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT laurineziane anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT ludoviccolombeau anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT celinefrochot anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT sergemordon anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT nadiradelhem anefficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT alexandrequilbe efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT oliviermorales efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT marthabaydoun efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT abhishekkumar efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT ramimustapha efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT takashimurakami efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT bertrandleroux efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT clementinedeschutter efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT elisethecua efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT laurineziane efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT ludoviccolombeau efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT celinefrochot efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT sergemordon efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma AT nadiradelhem efficientphotodynamictherapytreatmentforhumanpancreaticadenocarcinoma |
_version_ |
1725035611749875712 |
spelling |
doaj-22ff5a3083d6439cbf8a77ca51fc14402020-11-25T01:42:33ZengMDPI AGJournal of Clinical Medicine2077-03832020-01-019119210.3390/jcm9010192jcm9010192An Efficient Photodynamic Therapy Treatment for Human Pancreatic AdenocarcinomaAlexandre Quilbe0Olivier Moralès1Martha Baydoun2Abhishek Kumar3Rami Mustapha4Takashi Murakami5Bertrand Leroux6Clémentine de Schutter7Elise Thecua8Laurine Ziane9Ludovic Colombeau10Céline Frochot11Serge Mordon12Nadira Delhem13CNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceDepartment of Cancer Studies & Pharmaceutical Sciences New Hunt’s House, School of Life Sciences and Medicine, Guy’s Campus, King’s College London, London SE1 1UL, UKFaculty of Medicine, Saitama Medical University 38 Moro-Hongo, Moroyama, Ituma, Saitama 350-0495, JapanCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceUniv.Lille, Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, PhysicoPDT team or Immuno-PDT team, F-59000 Lille, FranceUniv.Lille, Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, PhysicoPDT team or Immuno-PDT team, F-59000 Lille, FranceLGRGP, UMR-CNRS 7274, University of Lorraine, F-54000 Nancy, FranceLGRGP, UMR-CNRS 7274, University of Lorraine, F-54000 Nancy, FranceUniv.Lille, Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, PhysicoPDT team or Immuno-PDT team, F-59000 Lille, FranceCNRS, UMR8161, Institut de Biologie de Lille, Université de Lille, Institut Pasteur de Lille, F-59021 Lille, FranceTo date, pancreatic adenocarcinoma (ADKP) is a devastating disease for which the incidence rate is close to the mortality rate. The survival rate has evolved only 2−5% in 45 years, highlighting the failure of current therapies. Otherwise, the use of photodynamic therapy (PDT), based on the use of an adapted photosensitizer (PS) has already proved its worth and has prompted a growing interest in the field of oncology. We have developed a new photosensitizer (PS-FOL/PS2), protected by a recently published patent (WO2019 016397-A1, 24 January 2019). This photosensitizer is associated with an addressing molecule (folic acid) targeting the folate receptor 1 (FOLR1) with a high affinity. Folate binds to FOLR1, in a specific way, expressed in 100% of ADKP or over-expressed in 30% of cases. The first objective of this study is to evaluate the effectiveness of this PS2-PDT in four ADKP cell lines: Capan-1, Capan-2, MiapaCa-2, and Panc-1. For this purpose, we first evaluated the gene and protein expression of FOLR1 on four ADKP cell lines. Subsequently, we evaluated PS2’s efficacy in our cell lines and we assessed the impact of PDT on the secretome of cancer cells and its impact on the immune system. Finally, we evaluate the PDT efficacy on a humanized SCID mouse model of pancreatic cancer. In a very interesting way, we observed a significant increase in the proliferation of activated-human PBMC when cultured with conditioned media of ADKP cancer cells subjected to PDT. Furthermore, to evaluate in vivo the impact of this new PS, we analyzed the tumor growth in a humanized SCID mice model of pancreatic cancer. Four conditions were tested: Untreated, mice (nontreated), mice with PS (PS2), mice subjected to illumination (Light only), and mice subjected to illumination in the presence of PS (PDT). We noticed that the mice subjected to PDT presented a strong decrease in the growth of the tumor over time after illumination. Our investigations have not only suggested that PS2-PDT is an effective therapy in the treatment of PDAC but also that it activates the immune system and could be considered as a real adjuvant for anti-cancer vaccination. Thus, this new study provides new treatment options for patients in a therapeutic impasse and will provide a new arsenal in the fight against PDAC.https://www.mdpi.com/2077-0383/9/1/192photodynamic therapyfolate-coupled photosensitizerpancreatic cancerimmuno-adjuvant |